anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A soluble microneedle patch containing deoxycholic acid and a preparation method and application thereof belong to the field of medicines. The invention provides a preparation and application of a soluble microneedle array patch containing deoxycholic acid in fat dissolution. Experimental results show that the microneedle patch is made of a biocompatible material and contains deoxycholic acid solid dispersion powder, and has double effects of dissolving fat and tightening skin. The research shows that the microneedle tip is uniform and has good mechanical strength and drug carrying capacity, and the effectiveness of the microneedle tip in transdermal drug delivery is verified through simulation and animal experiments. Therefore, the soluble microneedle array patch provides a new treatment scheme for the field of medicine, and has important clinical application prospect. Meanwhile, the embodiment optimizes the adjustment mass proportion, concentration, addition of adhesive and the like so as to improve the hardness and drug effect transmission efficiency of the microneedle, and provides important guidance and reference for further application of the preparation.
A dietary supplement system including three general components is provided. The first component is the fatty acid component and this includes sunflower seeds (containing omega 6 fatty acids), flax seed (containing omega 3 fatty acids) and powdered oils (containing omega 3 or omega 6 fatty acids and generally produced from sunflower oils). The weight ratio of omega 6 fatty acids to omega 3 fatty acids is 10:1 to 1:1, with 10:1 to 5:1 being preferred for normal animals and 2:1 to 1:1 being preferred for animals which have fatty acid responsive conditions. The second component is the GI component, which is used for facilitating animal gut health. This component includes prebiotics, probiotics and immunoglobulin (typically from albumin concentrate). The third component is the breed specific component and can include vitamins, minerals, additional fatty acids, antioxidants, amino acids, palatants, and nutraceutical additives.
Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O, and its structural formula is:

Carbidopa tablets contain 25 mg of carbidopa. Inactive ingredients are microcrystalline cellulose, FD&C Yellow No. 6, magnesium stearate and pregelatinized starch.

Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
PURPOSE: Pseudomonas genus microorganism HC1 is provided to environmentally-friendly treat the brown blotch disease of mushrooms by effectively resolving tolaasin. CONSTITUTION: Microorganisms with tolaasin resolution comprise the basic sequence of a sequence number 1, KACC91693. The culturing temperature of the microorganisms is in a range of 15-40°C. The culturing pH value of the microorganisms is in a range of 4.0-11.0. The microorganisms are cultured with one or more carbon sources selected from a group including fructose, galactose, saccharose, inositol, glycerol, dextrose, dextrin, Na-CMC, mannose, maltose, raffinose, cellobiose, ethanol, and sol lysine. The microorganisms are cultured with one or more organic nitrogen sources selected from a group including peptone, soytone, casaminoacid, tryptone, yeast extracts, and malt extracts.
Patients receive radium-223 dichloride as in Arm A and peposertib PO or BID on days 3-26. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, and CT or MRI throughout the study.
Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
Participants will be asked to take one tablet placebo daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to placebo. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
Hydrocephalus (HC) is a heterogenous disease characterized by alterations in cerebrospinal fluid (CSF) dynamics that may cause increased intracranial pressure. HC is a component of a wide array of genetic syndromes as well as a secondary consequence of brain injury (intraventricular hemorrhage (IVH), infection, etc.) that can present across the age spectrum, highlighting the phenotypic heterogeneity of the disease. Surgical treatments include ventricular shunting and endoscopic third ventriculostomy with or without choroid plexus cauterization, both of which are prone to failure, and no effective pharmacologic treatments for HC have been developed. Thus, there is an urgent need to understand the genetic architecture and molecular pathogenesis of HC. Without this knowledge, the development of preventive, diagnostic, and therapeutic measures is impeded. However, the genetics of HC is extraordinarily complex, based on studies of varying size, scope, and rigor. This review serves to provide a comprehensive overview of genes, pathways, mechanisms, and global impact of genetics contributing to all etiologies of HC in humans.
An initial meeting consisting of a screening, questionnaires, and a brief psychoeducation on imaginal exposure therapy, followed by 8-10 sessions with a licensed psychologist (the PI) or a clinical psychology graduate student who is supervised and trained by the PI. In Session 1, patients will create a script with the therapist on an eating disorder fear. In sessions 2-10 the therapist and patient will then imagine this eating disorder related fear based on the script. Each session will be modified to focus on "hot spots" or the most feared aspect of the script. Sessions will be audiotaped and videotaped and participants will be asked to listen to the sessions nightly for homework. Sessions will be weekly or twice per week for 8-10 weeks after the initial screening session.
Aim: To evaluate all-cause and liver-associated healthcare resource utilization (HCRU) and costs among patients with alpha-1 antitrypsin deficiency (AATD) with liver disease (LD) and/or lung disease (LgD). Materials & methods: This was a retrospective analysis of linked administrative claims data from the IQVIA PharMetrics® Plus and the IQVIA Ambulatory Electronic Medical Records (AEMR) databases from 1 July 2021 to 31 January 2022. Patients with AATD in the IQVIA PharMetrics Plus database were included with ≥1 inpatient or ≥2 outpatient medical claims ≥90 days apart with a diagnosis of AATD, or with records indicating a protease inhibitor (Pi)*ZZ/Pi*MZ genotype in the IQVIA AEMR database with linkage to IQVIA PharMetrics Plus. For a patient's identified continuous enrollment period, patient time was assigned to health states based on the initial encounter with an LD/LgD diagnosis. A unique index date was defined for each health state, and HCRU and costs were calculated per person-year (PPY). Results: Overall, 5136 adult and pediatric patients from the IQVIA PharMetrics Plus and IQVIA AEMR databases were analyzed. All-cause and liver-associated HCRU and costs were substantially higher following onset of LD/LgD. All-cause cost PPY ranged from US $11,877 in the absence of either LD/LgD to US $74,015 in the presence of both LD and LgD. Among liver transplant recipients in the AATD with LD health state, liver-associated total costs PPY were US $87,329 1-year pre-transplantation and US $461,752 1-year post-transplantation. In the AATD with LgD and AATD with LD and LgD health states, patients who received augmentation therapy were associated with higher all-cause total costs PPY and lower liver-associated total costs PPY than their counterparts who did not receive augmentation therapy. Conclusion: Patients with AATD had increased HCRU and healthcare costs in the presence of LD and/or LgD. HCRU and healthcare costs were highest in the AATD with LD and LgD health state.
FIELD: medicine, particularly, biological engineering. SUBSTANCE: object of this invention is production of monospecific sera for teichoic acids of staphylococci. This method of immunization prescribes intradermally administering teichoic acids together with Freind's adjuvant into different points in rabbits two times at two-week intervals, week later sampling blood from rabbit's heart, admixing it with teichoic acid and heparin and then administering the whole both intravenously and intraperitoneally. Disclosed method further prescribes that procedure be repeated in a week using doubled dose of teichoic acid. EFFECT: this method allows producing sera working in double diffusion reaction in gel diluted in ratio of 1 : 256 which bears witness to high titer of antibodies in prepared sera. 1 tbl
Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
A preparation for treating oral mucositis caused by paraquat. The preparation particularly includes following components: 250ml of a 0.9% sodium chloride solution, 0.16g of 2% lidocaine, 0.005g of dexamethasone and 0.08g of gentamicin. The preparation can reduce oral mucositis damage of a paraquat poisoning patient, can alleviating pain, can resist infection and can inhibit immunity. The preparation is used in a manner of mouth wash. A patient uses the preparation in the mouth-washing manner per 2 hours in daytime so that stimulation during local drug delivery is avoided and pain is alleviated. By means of frequent mouth washing, oral cavity can be moistened and large residue blocks and necrotic tissues can be removed. The preparation can reduce secretion and dental plaque, promotes a self-cleaning function of the oral cavity. A mouth washing liquid is low in cost and has an important clinical application value.
Patients will be recruited from the outpatient clinics in Shanghai Municipal Hospital and Shanghai Mental Health Center by Wechat and posters. A total of 204 eligible patients will be randomly allocated to two groups by a randomized block design: the electroacupuncture (EA) group (receiving EA treatment and taking the placebo drugs), and the antidepressants group (receiving sham acupuncture and taking the escitalopram ). After a one-week baseline evalauation, participants will enter a 9-month observation period in this trial, with a 3-month intervention period and a 6-month follow-up period. The interventiuon period will last for 12 weeks, with 3 sessions of real or sham acupuncture treatment per week for the first 8 weeks, and 2 sessions per week for the remaining 4 weeks. The escitalopram or the placebo will be given to the patients at a set time once a week during the 12-week intervention period, with daily oral dose of 10mg or up to 20mg as the maximum dose. Excperts in the Shanghai Mental Health Center will help the participants to adjust the drug dosage during the intervention period. The primary outcome is the 17-item Hamilton Rating Depression Sclae (HRDS-17) at week 12. The secondary outcomes include the recovery rate and the remission rate of depression, the Patient Health Questionnaire(PHQ-9) and the Medical Outcomes Study 36-Item Short Form (SF-36). Adverse effects will be assessed by the Treatment Emergent Symptom Scale through the trial. The software SPSS Version 24.0 for Windows will be used to do the data analysis. All statistical analyses will be based on the intention-to-treat (ITT) population of all randomly assigned patients, with a 2-sided significance level of less than 0.05.
<P>PROBLEM TO BE SOLVED: To prevent spoofing of a mobile terminal and an infrastructure sensor device.  <P>SOLUTION: The infrastructure sensor 1 collects sensor information, detected by a mobile sensor device 3 of a mobile terminal 4 owned by each user and transmits the sensor information to a center station 10 via a network 2. The center device 10 stores the sensor information. A user terminal 5 independently accesses the center device 10 via the network 2, such as the Internet, to acquire the sensor information stored in the center station 10. The device 1, the mobile terminal 4, and the center device 10 transmit and receive user verification information, including a challenge code as pseudo-random numbers and challenge code determining information, thereby conducting authentication.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Subjects included in the intervention group will receive a 14 week breathing technique program that will include: different types of breathing techniques (diaphragmatic, pursed-lips, alternate nostril breathing, etc.); progressive muscle relaxation techniques; and medical education about breathing.
Intramedullary nailing of unstable per- and subtrochanteric femoral fractures is a standard procedure in trauma and orthopaedic surgery. Unstable fractures treated with intramedullary nailing carry the risk of fracture fixation complications. The PFNA (Synthes) has evolved from the original PFN design, featuring a novel antirotation screw. Apart from the prevention of excess rotational forces, this supporting element may enhance the overall stability of the construct, thus potentially reducing fracture fixation complications. Empirical information about the fracture fixation complication rates of the PFNA device is not available. The primary objective of this study is to compare the 1-year fracture fixation rates between the PFNA and Gamma Nail 3™ (Stryker). Secondary objectives of the study are to compare differences in functional outcomes, quality of life outcomes, safety, radiological outcomes, handling and perceived effectiveness between the devices.
This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center (when more than 1 hospital or medical school team work on a medical research study), non-randomized, single-arm study of paliperidone ER in participants previously treated with risperidone with poor response. The study will consist of 2 phases: a main phase of 6 months and an extension phase of another 6 months. The total duration of the study will be 12 months. All participants will receive an oral (having to do with the mouth) daily dose of paliperidone ER in flexible dosage (in the range of 3-12 milligram \[mg\]: 3 mg, 6 mg, 9 mg, or 12 mg) according to Investigator's discretion. Efficacy and safety of participants will primarily be evaluated by Positive and Negative Syndrome Scale (PANSS) and Extrapyramidal Symptoms Rating Scale (ESRS), respectively. Participants' safety will be monitored throughout the study.
Pyridoxine dextrane sulphate of formula (I), for prevention and treatment of kidney stones is made by reacting pyridoxine for formula (V) in aq. soln. with sodium dextrane sulphate of formula (III) which has previously passed through Lewartite S-100 resin in protonic form. The final pH is kept at pH 3 approx. and the prod. separated by lyophilising as a yellowish-white powder with pyridoxine content 51-52% which decomposes at 220 deg.C.
In women with polycystic ovary syndrome (PCOS) androgen excess is fundamental to the clinical and physiological alterations of this disorder. In particular, androgen overproduction induces distinctive PCO morphology and appears to influence follicle function. Studies conducted in animals and nonhuman primates have demonstrated that androgens increase follicle number and in small antral follicles enhance granulosa cell (GC) responsiveness to gonadotropin stimulation. However, androgens also have been shown to clearly inhibit GC aromatase activity, and in PCOS follicular fluid, androgen content is abnormally increased. Efforts to reconcile these differences are nonexistent. Moreover, appropriate clinical studies to examine the effects of androgen on follicle health in women are lacking. Excessive androgen exposure in women due to functional tumors or high-dose testosterone treatment in F-M transsexuals has been associated with PCO morphology. Use of androgen therapy to promote follicle growth prior to ovarian hyperstimulation in women undergoing in vitro fertilization has not provided consistent results. However, in these studies GC responses to FSH were not carefully assessed, study populations were exclusively women with previously poor ovarian responses to FSH, and women with PCOS were not included. In fact, there are essentially no clinical studies that have addressed in detail the impact of androgen on follicle function in normal or PCOS women. We hypothesize that androgen facilitates GC responses to FSH in normal women and androgen excess further amplifies follicle growth and function in women with PCOS. We propose to study the effect of increased ovarian androgen on follicle function by increasing intraovarian androgen accumulation using aromatase inhibition followed by FSH stimulation. The experiments in this project are designed to provide insight into whether androgen excess facilitates or interferes with follicle function and ovulation in women with PCOS.
PURPOSE:To obtain a cosmetic improved in solubility of extract of Puerariae Radix, excellent in appearance and feeling of use and capable of exhibiting whitening effect extract of Puerariae Radix by combining extract of Puerariae Radix with a surfactant and polysaccarides or further adding polyol thereto. CONSTITUTION:An extract obtained by extracting root of pueraria with water, ethanol, propylene glycol, etc., its dried powder or a combined material of one or two or more ingredients separated from the extract is used as the extract of the root of pueraria. The extract is combined with a surfactant (preferably water-soluble nonionic surfactant such as polyoxyethylene alkyl ether) and polysaccharides (e.g. xanthan gum or gelatin) to provide the objective cosmetic. This cosmetic is further blended with a polyol such as ethylene glycol or diethylene glycol to provide the objective cosmetic further improved in solubility of extract of Puerariae Radix and capable of decreasing blend amount of the surfactant and polysaccharide. This cosmetic can be used as toilet lotion, beautifying liquid, etc.
Facial identity recognition (FIR) is arguably the ultimate form of recognition for the adult human brain. Even if the term prosopagnosia is reserved for exceptionally rare brain-damaged cases with a category-specific abrupt loss of FIR at adulthood, subjective and objective impairments or difficulties of FIR are common in the neuropsychological population. Here we provide a critical overview of the evaluation of FIR both for clinicians and researchers in neuropsychology. FIR impairments occur following many causes that should be identified objectively by both general and specific, behavioral and neural examinations. We refute the commonly used dissociation between perceptual and memory deficits/tests for FIR, since even a task involving the discrimination of unfamiliar face images presented side-by-side relies on cortical memories of faces in the right-lateralized ventral occipito-temporal cortex. Another frequently encountered confusion is between specific deficits of the FIR function and a more general impairment of semantic memory (of people), the latter being most often encountered following anterior temporal lobe damage. Many computerized tests aimed at evaluating FIR have appeared over the last two decades, as reviewed here. However, despite undeniable strengths, they often suffer from ecological limitations, difficulties of instruction, as well as a lack of consideration for processing speed and qualitative information. Taking into account these issues, a recently developed behavioral test with natural images manipulating face familiarity, stimulus inversion, and correct response times as a key variable appears promising. The measurement of electroencephalographic (EEG) activity in the frequency domain from fast periodic visual stimulation also appears as a particularly promising tool to complete and enhance the neuropsychological assessment of FIR.
PCT No. PCT/EP95/04049 Sec. 371 Date Apr. 14, 1997 Sec. 102(e) Date Apr. 14, 1997 PCT Filed Oct. 15, 1995 PCT Pub. No. WO96/11795 PCT Pub. Date Apr. 25, 1996A solidified drug supply for generating inhalable drug particles with the aid of a metering device includes a removal unit, with the drug supply being brittle and textureless. The density and the mechanical strength of the drug supply is abraded everywhere in such a way that the structure of the material removed from one side of the drug supply by the metering device is uniform across the entire usage region in the direction of the removal.
OBJECTIVE: Carotid artery web is a possible cause of ischemic stroke, especially in young patients who lack conventional risk factors. The immediate and long-term outcomes are not well studied. We aimed to determine the association between an ipsilateral carotid web and in-hospital stroke recurrence.
METHODS: We analyzed data from adult patients admitted with an acute anterior circulation large vessel occlusion at a Comprehensive Stroke Center between July 2015 and March 2023. The primary outcome was in-hospital stroke recurrence and secondary outcome was in-hospital recurrent LVO. Multivariable logistic regression was performed to examine the association between ipsilateral carotid web and recurrent ischemic stroke and recurrent LVO.
RESULTS: Of the 1463 patients with anterior circulation large vessel occlusion, 27 (1.8%) had an ipsilateral carotid artery web. Patients with carotid web were younger (median age (IQR), 60 years (53-67 years) versus 74 years (62-84 years), P < 0.01) and less likely to be Caucasian (60% vs. 80%, p = 0.014). Of the 27 patients with carotid web, 18 (70%) had no identifiable competing stroke mechanism. When compared to patients without ipsilateral carotid web, those with an ipsilateral carotid web had a higher risk of recurrent ischemic stroke (adjusted RR: 4.38, 95% CI: 1.38-13.85) and recurrent ipsilateral large vessel occlusion (adjusted RR: 4.49, 95% CI: 1.41-14.21).
INTERPRETATION: Carotid webs are an under recognized cause of acute large vessel occlusion and are associated with higher risk of early recurrence. Studies are needed to validate our findings and test early revascularization strategies in patients with symptomatic carotid artery webs.